Fig. 2: HMGA2 expression in AML cytogenetic and mutation subgroups.
From: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
Upper panel. The HMGA2 RT-qPCR test shows a large range of expression values among cytogenetic and mutation subgroups of the training cohort. HMGA2 expression levels evaluated by this test were normalized on the ABL1 control gene and expressed as NCN. The dotted line represents the assay cutoff established at 1100 NCN. Bottom panel. Frequency of patients classified in each subgroup according to the HMGA2 expression profile. Numbers in white represent HMGA2+ patients. ELN 2017 and cytogenetic risk subgroups were evaluated in the training cohort (n = 358), mutations were obtained by RNA sequencing in 263 samples of the training cohort. Abn., abnormal; biCEBPA, biallelic CEBPA mutations; ELN: European LeukemiaNet; HMGA2+ , high expression (≥1100 NCN); HMGA2−, low expression (<1100 NCN); NCN, Normalized Copy Numbers; NK, normal karyotype
